| 영문 | prostaglandin(s)=PG(s) | 한글 | 푸로스타글란딘 |
|---|---|---|---|
| 설명 | 세포막의 인지질이 인지질 분해효소-A2에 의하여 유리된 arachidonic acid의 대사산물 중 cyclooxygenase에 의하여 형성된 물질. 여러 가지 종류가 있으며 복잡한 약리 작용을 한다. 대개, 혈관을 확장시키며, 민무늬근을 수축 또는 이완시키는데, 특히 자궁과 기관지근에 예민하게 작용한다. 종류를 보면, PGI2는 강력한 혈소판 응집 억제 작용을 하며, PGE계통은 위산분비 및 펩신분비를 강력히 억제시키며, 이자분비도 억제한다. 그 외 체온 조절 및 동통의 신경전도 등 아주 많은 작용을 하는 인체에 아주 중요한 물질이다. |
||
| PGI | phosphoglucose isomerase; potassium, glucose, and insulin; prostaglandin I |
|---|---|
| DAE | diphenylanthracene endoperoxide; diving air embolism; dysbaric air embolism |
| EP | echo planar; ectopic pregnancy; edible portion; electrophoresis; electrophysiologic; electroprecipit... |
| TB | Taussig-Bind [syndrome]; terabyte; term birth; terminal bronchiole; terminal bronchus; thromboxane B... |
| TBX | thromboxane; total body irradiation |
| PGHS-1 | Prostaglandin endoperoxide H synthase-1 |
|---|---|
| PGHS | Prostaglandin endoperoxide H synthases |
| PGS | Prostaglandin endoperoxide synthase |
| PGHS-2 | prostaglandin endoperoxide G/H synthase 2 |
| TXA2/PGH2 | Thromboxane A2/prostaglandin H2 |
thromboxane
| prostaglandin endoperoxide thromboxane isomerase | <enzyme> Converts prostaglandin h2 to thromboxane b2 and 12l-hydroxy-5,8,10-heptadecatrienoic acid Registry number: EC 5.3.99.- Synonym: endoperoxide-tx isomerase, pg endoperoxide thromboxane isomerase (26 Jun 1999) |
|---|
| prostaglandin endoperoxide synthase | <enzyme> An enzyme complex that catalyses the formation of prostaglandins from the appropriate unsaturated fatty acid, molecular oxygen, and a reduced acceptor. See: cyclooxygenase Chemical name: (5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase Registry number: EC 1.14.99.1 (12 Dec 1998) |
|---|---|
| prostaglandin R2 D-isomerase | <enzyme> Prostaglandin d synthase and pgd synthase were non-print entry terms to prostaglandin synthase 1983-91 Registry number: EC 5.3.99.2 Synonym: prostaglandin endoperoxide d-isomerase, prostaglandin h2 d-isomerase, pgd2 isomerase, prostaglandin d2-isomerase, prostaglandin d2 isomerase, pgd synthetase, pgr2 d-isomerase, prostaglandin d synthase, pgd synthase, pgd2 synthase, prostaglandin d2 synthase (26 Jun 1999) |
| endoperoxide | A peroxide (-O-O-) group that bridges two atoms that are both parts of a larger molecule. (05 Mar 2000) |
| receptors, thromboxane | Cell surface proteins that bind thromboxanes with high affinity and trigger intracellular changes influencing the behaviour of cells. at least a subset of thromboxane receptors act via the inositol phosphate and diacylglycerol second messenger systems. (12 Dec 1998) |
| thromboxane | <biochemistry> Arachidonic acid metabolites produced by the action of thromboxane synthetase on prostaglandin cyclic endoperoxides. Thromboxane A2 (TxA2) is a potent inducer of platelet aggregation and release and although unstable, the activation of platelets leads to the further production of TxA2. Also causes arteriolar constriction. Another endoperoxide product, prostacyclin, has the opposite effects. (18 Nov 1997) |
| thromboxane a2 | <chemical> An unstable intermediate between the prostaglandin endoperoxides and thromboxane b2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (rcs). Chemical name: Thromboxa-5,13-dien-1-oic acid, 9,11-epoxy-15-hydroxy-, (5Z,9alpha,11alpha,13E,15S)- (12 Dec 1998) |
| thromboxane-a synthase | <enzyme> An enzyme found predominantly in platelet microsomes. It catalyses the conversion of pgg(2) and pgh(2) (prostaglandin endoperoxides) to thromboxane a2. Chemical name: (5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate thromboxane-A(2)-isomerase Registry number: EC 5.3.99.5 (12 Dec 1998) |
| thromboxane b2 | <chemical> A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). Chemical name: Thromboxa-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,13E,15S)- (12 Dec 1998) |
| thromboxane dehydrogenase | <enzyme> Converts thromboxane b2 to 11-dehydro-thromboxane b2, but not the reverse reaction; uses nad but not nadp as cofactor; only attacks the 11-hydroxy group of txb2 Registry number: EC 1.1.1.- Synonym: thromboxane b2 dehydrogenase, 11-hydroxythromboxane b2 dehydrogenase, 11-hydroxy-txb2 dehydrogenase (26 Jun 1999) |
| receptors, prostaglandin | Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behaviour of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin d2 (dp receptors), prostaglandin e2 (ep1, ep2, and ep3 receptors), prostaglandin f2-alpha (fp receptors), and prostacyclin (ip receptors). (12 Dec 1998) |
| receptors, prostaglandin e | Cell surface receptors which bind prostaglandins with a high affinity and trigger intracellular changes which influence the behaviour of cells. Prostaglandin e receptors prefer prostaglandin e2 to other endogenous prostaglandins. They are subdivided into ep1, ep2, and ep3 types based on their effects and their pharmacology. (12 Dec 1998) |
| prostaglandin | <protein> (prostate gland + in because they were originally discovered in semen) any of a group of components derived from unsaturated 20 carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway that are extremely potent mediators of a diverse group of physiologic processes. The abbreviation for prostaglandin is PG, specific compounds are designated by adding one of the letters A through I to indicate the type of substituents found on the hydrocarbon skeleton and a subscript (1, 2 or 3) to indicate the number of double bonds in the hydrocarbon skeleton for example, PGE2. The predominant naturally occurring prostaglandins all have two double bonds and are synthesised from arachidonic acid (5, 8, 11, 14 eicosatetraenoic acid) by the pathway shown in the illustration. The 1 series and 3 series are produced by the same pathway with fatty acids having one fewer double bond (8, 11, 14 eicosatrienoic acid or one more double bond (5, 8, 11, 14, 17 eicosapentaenoic acid) than arachidonic acid. The subscript a or á indicates the configuration at C 9 (a denotes a substituent below the plane of the ring, á, above the plane). The naturally occurring PGF's have the a configuration, for example, PGF2a. All of the prostaglandins act by binding to specific cell surface receptors causing an increase in the level of the intracellular second messenger cyclic AMP (and in some cases cyclic GMP also). The effect produced by the cyclic AMP increase depends on the specific cell type. In some cases there is also a positive feedback effect. Increased cyclic AMP increases prostaglandin synthesis leading to further increases in cyclic AMP. Group of compounds derived from arachidonic acid by the action of cyclooxygenase that produces cyclic endoperoxides (PGG2 and PGH2) that can give rise to prostacyclin or thromboxanes as well as prostaglandins. Were originally purified from prostate (hence the name), but are now known to be ubiquitous in tissues. PGs have a variety of important roles in regulating cellular activities, especially in the inflammatory response where they may act as vasodilators in the vascular system, cause vasoconstriction or vasodilation together with bronchodilation in the lung and act as hyperalgesics. Prostaglandins are rapidly degraded in the lungs and will not therefore persist in the circulation. Prostaglandin E2 PGE2) acts on adenylate cyclase to enhance the production of cyclic AMP. (18 Nov 1997) |
| prostaglandin antagonists | Compounds that inhibit the action of prostaglandins. (12 Dec 1998) |
| prostaglandin d2 | <chemical> 9,15-dihydroxy-11-oxoprosta-5,13-dien-1-oic acid. The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesised by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. Chemical name: Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-oxo-, (5Z,9alpha,13E,15S)- (12 Dec 1998) |
| prostaglandin E1 | <chemical> A potent vasodilator agent that increases peripheral blood flow. It inhibits platelet aggregation and has many other biological effects such as bronchodilation, mediation of inflammation, etc. Pharmacological action: fibrinolytic agent, platelet aggregation inhibitors, vasodilator agents. Chemical name: Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)- (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|